EyePoint Pharmaceuticals, Inc. Board of Directors

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Dr. Jay S. Duker M.D.

Dr. Jay S. Duker M.D.

President, CEO & Director

Mr. Michael J. Maciocio

Mr. Michael J. Maciocio

Chief Manufacturing Officer

Ms. Jennifer Leonard

Ms. Jennifer Leonard

Chief People Officer & Senior VP of IT

Mr. Ron I. Honig Esq.

Mr. Ron I. Honig Esq.

Chief Legal Officer & Company Secretary

Ms. Isabelle Lefebvre

Ms. Isabelle Lefebvre

Chief Regulatory Officer

Mr. Michael Pine

Mr. Michael Pine

Chief Business Officer

Mr. David Scott Jones M.A.

Mr. David Scott Jones M.A.

Senior VP & Chief Commercial Officer

Dr. Marcia Sellos-Moura Ph.D.

Dr. Marcia Sellos-Moura Ph.D.

Senior VP and Head of Development & Program Management

Comments